169 related articles for article (PubMed ID: 28370075)
21. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.
Sicras-Mainar A; Rejas J; Navarro-Artieda R; Aguado-Jodar A; Ruiz-Torrejón A; Ibáñez-Nolla J; Kvasz M
Int Urogynecol J; 2014 Apr; 25(4):485-92. PubMed ID: 24196653
[TBL] [Abstract][Full Text] [Related]
22. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation.
Cardozo L; Hall T; Ryan J; Ebel Bitoun C; Kausar I; Darekar A; Wagg A
Int Urogynecol J; 2012 Nov; 23(11):1581-90. PubMed ID: 22576329
[TBL] [Abstract][Full Text] [Related]
24. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
25. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
26. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly.
Rangganata E; Widia F; Rahardjo HE
Acta Med Indones; 2020 Jul; 52(3):255-263. PubMed ID: 33020336
[TBL] [Abstract][Full Text] [Related]
27. Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder.
Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR
Int J Geriatr Psychiatry; 2021 May; 36(5):684-696. PubMed ID: 33169433
[TBL] [Abstract][Full Text] [Related]
28. Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.
Kachru N; Sura S; Chatterjee S; Aparasu RR
Drugs Aging; 2016 Oct; 33(10):755-763. PubMed ID: 27681701
[TBL] [Abstract][Full Text] [Related]
29. Antimuscarinic use and discontinuation in an older adult population.
Vouri SM; Schootman M; Strope SA; Xian H; Olsen MA
Arch Gerontol Geriatr; 2019; 80():1-11. PubMed ID: 30268971
[TBL] [Abstract][Full Text] [Related]
30. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
[TBL] [Abstract][Full Text] [Related]
31. Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.
Hsiao SM; Lin HH; Kuo HC
Low Urin Tract Symptoms; 2018 Jan; 10(1):21-26. PubMed ID: 27515567
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
[TBL] [Abstract][Full Text] [Related]
33. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
35. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
[TBL] [Abstract][Full Text] [Related]
36. Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
Akino H; Namiki M; Suzuki K; Fuse H; Kitagawa Y; Miyazawa K; Fujiuchi Y; Yokoyama O
Int J Urol; 2014 Apr; 21(4):389-94. PubMed ID: 24118296
[TBL] [Abstract][Full Text] [Related]
37. Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin.
Tijnagel MJ; Scheepe JR; Blok BF
BMC Urol; 2017 Apr; 17(1):30. PubMed ID: 28403849
[TBL] [Abstract][Full Text] [Related]
38. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Aguado-Jodar A; Ruíz-Torrejón A
Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder.
Armstrong EP; Malone DC; Bui CN
J Med Econ; 2012; 15 Suppl 1():35-44. PubMed ID: 22998646
[TBL] [Abstract][Full Text] [Related]
40. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.
McKeage K
Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
